1. Home
  2. STKE vs VERU Comparison

STKE vs VERU Comparison

Compare STKE & VERU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

STKE

Sol Strategies Inc.

N/A

Current Price

$1.11

Market Cap

38.3M

Sector

N/A

ML Signal

N/A

Logo Veru Inc.

VERU

Veru Inc.

HOLD

Current Price

$2.40

Market Cap

40.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
STKE
VERU
Founded
2002
1971
Country
Canada
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
38.3M
40.9M
IPO Year
N/A
1996

Fundamental Metrics

Financial Performance
Metric
STKE
VERU
Price
$1.11
$2.40
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$22.50
AVG Volume (30 Days)
269.9K
48.9K
Earning Date
05-15-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$16,296,958.00
Revenue This Year
N/A
N/A
Revenue Next Year
$552.94
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.85
$0.36
52 Week High
$7.75
$4.59

Technical Indicators

Market Signals
Indicator
STKE
VERU
Relative Strength Index (RSI) 48.34 51.85
Support Level $0.85 $2.13
Resistance Level $1.65 $2.70
Average True Range (ATR) 0.10 0.13
MACD 0.02 0.02
Stochastic Oscillator 65.67 62.94

Price Performance

Historical Comparison
STKE
VERU

About STKE Sol Strategies Inc.

Sol Strategies Inc is engaged in investing in blockchain technologies and crypto currencies. Company executes its Investment Objective through three lines of effort: Treasury management: Maintaining a core portfolio of cryptocurrencies for long-term growth, enhanced with risk management strategies to minimize volatility, and generating yield through lending, staking, and liquidity provisioning; Private equity focused on early stage companies in the DeFi and blockchain sectors; and Active investments to generate yield through strategic activities, including Bitcoin mining and stalking and validating Solana.

About VERU Veru Inc.

Veru Inc is a late clinical-stage biopharmaceutical focused on developing medicines for the treatment of cardiometabolic and inflammatory diseases. Its drug development program consists of two late-stage new chemical entities, enobosarm and sabizabulin. Enobosarm, an oral selective androgen receptor modulator, is being developed to make weight reduction by GLP-1 RA drugs more tissue selective for loss of fat and preservation of lean mass, and is planned for a Phase 2b PLATEAU clinical study in obesity. Sabizabulin, an oral microtubule disruptor, is being developed for the treatment of inflammation in atherosclerotic cardiovascular disease to lower high-sensitivity CRP in patients with stable coronary artery disease, with a planned Phase 2 study.

Share on Social Networks: